Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIO-Q is a nutraceutical formulation developed by Miotic Pharmaceuticals, designed as a combination supplement containing Coenzyme Q10 (ubidecarenone), L-carnitine (levocarnitine), and a complex of vitamins. Coenzyme Q10 is an essential cofactor in the mitochondrial electron transport chain, facilitating ATP production and providing antioxidant defense against oxidative stress. L-carnitine plays a critical role in energy metabolism by transporting long-chain fatty acids into the mitochondria for beta-oxidation. This combination is typically utilized to support mitochondrial health, improve cellular energy levels, and manage conditions associated with oxidative stress or metabolic insufficiency, such as cardiovascular issues or certain types of idiopathic infertility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MIO-Q.